Totadri S,Radhakrishnan V,Ganesan TS,Ganesan P,Kannan K,Lakshmipathy KM .2017 .Can radiotherapy be omitted in children with Hodgkin lymphoma who achieve metabolic remission on interim positron emission tomography? Experience of a tertiary care cancer referral center. J Glob Oncol, 009340 : 1-7.
Korholz CM,Parker JL,Balwierz W,Ammann RA,Anderson RA,Attarbaschi A .2022 .Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): A titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. (21), 10(1) : 470-8.
Lo AC,Dieckmann K,Pelz T,Evans EG,Cabillic RE,Vordermark D .2021 .Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer, 10(Suppl 2) : .
Venkatramani R,Kamath S,Wong K,Olch AJ,Malvar J,Sposto R .2014 .Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved eld radiation. Pediatr Blood Cancer, 10(7) : 1277-81.
Kelly KM,Cole PD,Pei Q,Bush R,Roberts KB,Hodgson DC .2019 .Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the children's oncology group. Br J Haematol, 10(1) : 39-48.
Marr KC,Connors JM,Savage KJ,Goddard KJ,Deyell RJ .2017 .ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol, 10(4) : 849-54.
Benetou DR,Stergianos E,Geropeppa M,Ntinopoulou E,Tzanni M,Pourtsidis A .2018 .Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: A systematic review. Hellenic J Cardiol, 09(3) : 152-64.
'Brien O,Donaldson MM,Balise SS,Whittemore RR,Link AS,MP AS .2009 .Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol, 24(1) : 1232-9.
Inskip PD,Veiga LHS,Brenner AV,Sigurdson AJ,Ostroumova E,Chow EJ .2019 .Hyperthyroidism after radiation therapy for childhood cancer: A report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys, 02(2) : 415-24.
Song KJ,Park JH,Im HJ,Ahn SD .2020 .Survival and long-term toxicities of pediatric Hodgkin lymphoma after combined modality treatment: A single institute experience. Radiat Oncol J, 00346(3) : 198-206.
Jones LW,Liu Q,Armstrong GT,Ness KK,Yasui Y,Devine K .2014 .Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: A report from the childhood cancer survivor study. J Clin Oncol, 56(32) : 3643-50.
Adam M,Bekueretsion Y,Abubeker A,Tadesse F,Kwiecinska A,Howe R .2021 .Clinical characteristics and histopathologicalp Patterns of Hodgkin lymphoma and treatment outcomes at a tertiary cancer center in Ethiopia. JCO Glob Oncol, 10 : 277-88.
Radhakrishnan V,Dhanushkodi M,Ganesan TS,Ganesan P,Sundersingh S,Selvaluxmy G .2016 .Pediatric Hodgkin lymphoma treated at cancer institute, Chennai, India: Longterm outcome. J Glob Oncol, 005314(5) : 545-54.
Belgaumi A,Al-Ko de AA,Khafaga Y,Joseph N,Malik RJ,Siddiqui KS .2009 .Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematol Oncol Stem Cell Ther, 3876(09) : 50038-6.
Hazarika M,Sutnga C,Raj DN,Roy PS,Sarangi SS,Reddy R .2023 .Pediatric Hodgkin s lymphoma: Experience from a tertiary cancer center in North East India. Int J Contemp Pediatrics, 10(2) : 2349-3291.
Palayullakandi A,Trehan A,Jain R,Kumar R,Mittal BR,Kapoor R .2022 .Retrospective single-center experience with OEPA/COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting. Pediatr Hematol Oncol, 2044418(7) : 587-99.
Kahn JM,Pei Q,Friedman DL,Kaplan J,Keller FG,Hodgson D .2022 .Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: A retrospective pooled analysis of children s oncology group trials. Lancet Haematol, 3026(21) : 00349-5.
Parambil BC,Narula G,Prasad M,Shah S,Shet T,Shridhar E .2020 .l Clinical pro le and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. Pediatr Blood Cancer, 10(2) : .